D. Provencher

C. Le Page, D. Huntsman, M. Köbel, 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies.

A. Mes-Masson, D. Provencher, D. Fink, 1994, Experimental cell research.

Germline TP53 mutational spectrum in French Canadians with breast cancer

A. Mes-Masson, W. Foulkes, D. Provencher, 2015, BMC Medical Genetics.

The molecular origin and taxonomy of mucinous ovarian carcinoma

Kylie L. Gorringe, S. Fox, N. Traficante, 2019, Nature Communications.

SOGC CLINICAL PRACTICE GUIDELINES Canadian Consensus Guidelines on Human Papillomavirus

D. Provencher, P. Bryson, 2007 .

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis

A. Mes-Masson, J. Madore, D. Provencher, 2013, BMC Cancer.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Small Cell Cancers

D. Provencher, M. Friedlander, A. Fyles, 2014, International Journal of Gynecologic Cancer.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

E. Eisenhauer, A. Oza, D. Provencher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer.

D. Provencher, P. Drakopoulos, T. Warkus, 2019, Gynecologic oncology.

Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling

Anne-Marie Mes-Masson, Véronique Ouellet, Thomas J Hudson, 2005, Oncogene.

Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.

A. Mes-Masson, D. Provencher, P. Tonin, 2012, International journal of oncology.

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

C. Le Page, A. Mes-Masson, J. Madore, 2007, Cancer.

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer

T. Hudson, C. Le Page, A. Mes-Masson, 2006, British Journal of Cancer.

BMP-2 signaling in ovarian cancer and its association with poor prognosis

C. Le Page, A. Mes-Masson, D. Provencher, 2009, Journal of ovarian research.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

D. Provencher, M. Birrer, I. Vergote, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer.

D. Provencher, S. Rubin, J. Lewis, 1991, American journal of obstetrics and gynecology.

Phase II multicenter open‐label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies

G. Pond, A. Oza, K. Swenerton, 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix

D. Provencher, E. Franco, A. Ferenczy, 2012, Journal of Clinical Microbiology.

Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix

D. Provencher, E. Franco, A. Ferenczy, 2010, Journal of Clinical Microbiology.

The Role of HPV Testing

D. Provencher, K. J. Murphy, 2007 .

Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix

D. Provencher, E. Franco, A. Koushik, 2002, Journal of medical virology.

Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2002, Molecular carcinogenesis.

Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations

C. Greenwood, A. Mes-Masson, W. Foulkes, 2004, International journal of cancer.

Gravity-based microfiltration reveals unexpected prevalence of circulating tumor cell clusters in ovarian and colorectal cancer

A. Mes-Masson, D. Provencher, D. Juncker, 2019, bioRxiv.

A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma

C. Le Page, A. Mes-Masson, M. Köbel, 2019, The journal of pathology. Clinical research.

Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions.

D. Provencher, S. Rubin, J. Lewis, 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Mutations in a 10‐bp polyadenine repeat of transforming growth factor β‐receptor type II gene is an infrequent event in human epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2000, Clinical genetics.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes

Ali Bashashati, Richard A. Moore, Gavin Ha, 2017, Nature Genetics.

Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A

A. Mes-Masson, D. Provencher, P. Tonin, 2004, Cancer Chemotherapy and Pharmacology.

OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer.

A. Mes-Masson, D. Provencher, P. Tonin, 2005, International journal of oncology.

Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites

A. Mes-Masson, D. Provencher, P. Tonin, 1999, Molecular carcinogenesis.

Canadian Consensus Guidelines on Human Papillomavirus

D. Provencher, J. Frappier, V. Senikas, 2007 .

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.

P. Fasching, D. Provencher, I. Ray-Coquard, 2021, Gynecologic oncology.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

D. Provencher, H. Hirte, I. Vergote, 2012, The Lancet. Oncology.

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

H. Putter, B. Monk, D. Provencher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

A. Tinker, A. Oza, D. Provencher, 2022, Current oncology.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018 .

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

B. Monk, B. Karlan, A. Oza, 2014 .

Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.

D. Provencher, R. Mannel, J. Kelley, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

A. Tinker, R. Wenham, D. Provencher, 2019, Gynecologic oncology.

Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.

D. Provencher, P. Saigo, S. Rubin, 1990 .

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers

A. Mes-Masson, D. Provencher, P. Tonin, 2000, Oncogene.

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

H. Mackay, E. Eisenhauer, D. Provencher, 2016 .

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

B. Monk, A. Oza, R. Wenham, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

B. Monk, B. Karlan, A. Oza, 2015 .

Positive Adnexal or Uterine Serosal Involvement in Stage IIIC Endometrial Cancer Is an Adverse Factor for Recurrence

D. Provencher, P. Gauthier, P. Petignat, 2008, Gynecologic and Obstetric Investigation.

Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

D. Provencher, K. Gaarenstroom, V. Zanagnolo, 2016, Gynecologic oncology.

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

B. Monk, M. Morgan, D. Provencher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐risk human papillomavirus infection of the genital tract of women with a previous history or current high‐grade vulvar intraepithelial neoplasia

D. Provencher, E. Franco, F. Coutlée, 2006, Journal of medical virology.

Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer.

A. Mes-Masson, D. Provencher, K. Rahimi, 2017, Human pathology.

The future of HPV testing in clinical laboratories and applied virology research.

D. Provencher, E. Franco, F. Coutlée, 1997, Clinical and diagnostic virology.

A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b

E. Eisenhauer, A. Oza, D. Provencher, 2008 .

Haplotype Analysis of BRCA2 8765delAG Mutation Carriers in French Canadian and Yemenite Jewish Hereditary Breast Cancer Families

A. Mes-Masson, W. Foulkes, D. Provencher, 2001, Human Heredity.

Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma

A. Mes-Masson, D. Provencher, V. Barrès, 2015, BioMed research international.

Screening histories and contact with physicians as determinants of cervical cancer risk in Montreal, Quebec.

J. Hanley, D. Provencher, E. Franco, 2014, Current oncology.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

C. Le Page, A. Mes-Masson, D. Huntsman, 2013, Biopreservation and biobanking.

Trisomy of chromosome 10 in two cases of ovarian carcinoma.

A. Mes-Masson, D. Provencher, P. Tonin, 2000, Cancer genetics and cytogenetics.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

E. Kohn, A. Okamoto, D. Provencher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Absence of human papillomavirus sequences in ovarian pathologies

A. Mes-Masson, D. Provencher, F. Coutlée, 1995, Journal of clinical microbiology.

Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix.

C. Wheeler, D. Provencher, E. Franco, 2003, American journal of obstetrics and gynecology.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for High-Grade Undifferentiated Sarcomas of the Uterus

D. Provencher, I. Ray-Coquard, P. Harter, 2014, International Journal of Gynecologic Cancer.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors)

Jae-Weon Kim, D. Provencher, J. Ledermann, 2014, International Journal of Gynecologic Cancer.

Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.

D. Provencher, H. V. van Doorn, G. D. de Bock, 2016, Gynecologic oncology.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Deena M. A. Gendoo, Kathleen M Spring, Gregory M. Chen, 2015, Cancer research.

Vaginal Epithelioid Angiosarcoma: A Potential Pitfall in Gynecologic Pathology

D. Provencher, M. Richer, M. Barkati, 2014, Journal of lower genital tract disease.

SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study

C. Le Page, A. Mes-Masson, G. Turashvili, 2021, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

D. Provencher, J. Ledermann, M. Birrer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of three new serous epithelial ovarian cancer cell lines

A. Mes-Masson, J. Madore, D. Provencher, 2008, BMC Cancer.

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent

A. Mes-Masson, D. Provencher, P. Tonin, 2008, BMC Cancer.

Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk

D. Provencher, J. Siemiatycki, K. Aronson, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.

S. Bens, R. Siebert, A. Mes-Masson, 2017, Cancer research.

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

Kylie L. Gorringe, A. Talhouk, A. Mes-Masson, 2022, npj Precision Oncology.

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

A. Tinker, A. Oza, D. Provencher, 2021, Nature Communications.

Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

Kylie L. Gorringe, D. Etemadmoghadam, D. Bowtell, 2020, The Journal of pathology.

Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.

C. Le Page, A. Mes-Masson, M. Köbel, 2019, Current drug targets.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

A. Mes-Masson, W. Foulkes, D. Provencher, 1998, American journal of human genetics.

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2021, Genome medicine.

The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene

J. Ragoussis, C. Greenwood, A. Mes-Masson, 2020, medRxiv.

Clinical Trials in Recurrent Ovarian Cancer

D. Alberts, A. Tinker, E. Trimble, 2011, International Journal of Gynecologic Cancer.

Vers un dépistage possible du cancer de l’ovaire ?

D. Provencher, F. Penault-llorca, G. Chêne, 2013 .

Characterization of the 3p12.3‐pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer

A. Mes-Masson, D. Provencher, P. Tonin, 2009, Molecular carcinogenesis.

RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2014, PloS one.

Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region

T. Hudson, A. Mes-Masson, D. Provencher, 2004, Molecular carcinogenesis.

Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.

A. Talhouk, M. Köbel, D. Provencher, 2020, Gynecologic oncology.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

C. Le Page, A. Mes-Masson, D. Huntsman, 2018, BMC Cancer.

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing

S. Leung, E. Goode, C. Le Page, 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.

A. Mes-Masson, D. Provencher, P. Tonin, 2013, International journal of oncology.

Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis

Manuela M. Santos, C. Le Page, A. Mes-Masson, 2011, International journal of cancer.

Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies

C. Le Page, A. Mes-Masson, D. Huntsman, 2010, Cancers.

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

A. Mes-Masson, D. Huntsman, M. Köbel, 2010, The Journal of pathology.

Protease inhibitor SERPINA1 expression in epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2010, Clinical & Experimental Metastasis.

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis

A. Mes-Masson, J. Madore, D. Provencher, 2013, BMC Cancer.

Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer

W. Foulkes, D. Provencher, P. Tonin, 2021, Scientific Reports.

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome

C. Greenwood, A. Mes-Masson, J. Madore, 2012, PloS one.

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Kylie L. Gorringe, S. Fox, P. Fasching, 2020, Modern Pathology.

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

A. Oza, R. Wenham, D. Provencher, 2020, Clinical Cancer Research.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

B. Monk, B. Karlan, A. Oza, 2014, The Lancet. Oncology.

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.

A. Tinker, A. Oza, D. Provencher, 2021, Gynecologic oncology.

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis

D. Provencher, C. Aghajanian, K. Cadoo, 2022, Gynecologic oncology.

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

H. Mackay, E. Eisenhauer, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.

A. Oza, D. Provencher, W. Miller, 2009, Gynecologic oncology.

Signature of a silent killer: expression profiling in epithelial ovarian cancer

Anne-Marie Mes-Masson, Véronique Ouellet, C. Le Page, 2004, Expert review of molecular diagnostics.

Cellular senescence is a central response to cytotoxic chemotherapy in high-grade serous ovarian cancer

A. Mes-Masson, D. Provencher, F. Rodier, 2018, bioRxiv.

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity

A. Mes-Masson, D. Provencher, P. Tonin, 2012, Oncogenesis.

Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes

A. Mes-Masson, D. Provencher, P. Tonin, 2007, International Journal of Gynecologic Cancer.

Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.

T. Hudson, A. Mes-Masson, D. Provencher, 2007, International journal of oncology.

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Proteome profiling of human epithelial ovarian cancer cell line TOV-112D

Arnaud Droit, Anne-Marie Mes-Masson, Guy G. Poirier, 2005, Molecular and Cellular Biochemistry.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors

D. Provencher, J. Ledermann, R. Glasspool, 2014, International Journal of Gynecologic Cancer.

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

A. Mes-Masson, J. Madore, D. Provencher, 2008, BMC Cancer.

Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.

B. Monk, D. Provencher, Y. Park, 2011, Gynecologic oncology.

Pleomorphic Undifferentiated Uterine Sarcoma in a Young Patient Presenting With Elevated Beta-hCG and Rare Variants of Benign Leiomyoma: A Case Report and Review of the Literature

D. Provencher, K. Rahimi, P. Sauthier, 2019, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

Anne-Marie Mes-Masson, Liliane Meunier, A. Mes-Masson, 2012, BMC Cancer.

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.

D. Provencher, S. Memarzadeh, U. Matulonis, 2022, Journal of Clinical Oncology.

Uterine serous carcinoma.

B. Monk, D. Provencher, A. Mariani, 2021, Gynecologic oncology.

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

A. Tinker, D. Provencher, L. Seymour, 2019, Clinical Cancer Research.

LYMPHANGIOMA CIRCUMSCRIPTUM OF THE VULVA: CASE REPORT AND REVIEW OF THE LITERATURE

D. Provencher, M. Penalver, P. Ganjei, 1989, Obstetrics and gynecology.

Spindle Cell Epithelioma of the Vagina

D. Provencher, P. Gauthier, C. Matte, 2015, International journal of surgical pathology.

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

A. Tinker, A. Oza, D. Provencher, 2018, The Lancet. Oncology.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma

D. Provencher, R. Glasspool, G. Kristensen, 2014, International Journal of Gynecologic Cancer.

Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1‐q25.2

K. Dewar, A. Mes-Masson, D. Provencher, 2005, Molecular carcinogenesis.

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Cesar M. Castro, James X. Sun, A. Tinker, 2017, Gynecologic oncology.

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease

A. Mes-Masson, D. Provencher, P. Tonin, 2015, Genes & cancer.

V. Gebski, D. Provencher, D. Eek, 2018, The Lancet. Oncology.

Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)

Anne-Marie Mes-Masson, Abdelali Filali-Mouhim, A. Mes-Masson, 2007, Molecular carcinogenesis.

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence

A. Mes-Masson, D. Provencher, F. Rodier, 2019, Nature Communications.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Small Cell Carcinoma of the Cervix

D. Provencher, J. Ledermann, I. Treilleux, 2014, International Journal of Gynecologic Cancer.

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

A. Mes-Masson, D. Provencher, P. Tonin, 2015, BMC Cancer.

Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Thomas Gervais, Tamal Das, Anne-Marie Mes-Masson, 2013, Biomicrofluidics.

BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis

C. Le Page, A. Mes-Masson, J. Madore, 2012, PloS one.

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families

A. Mes-Masson, W. Foulkes, D. Provencher, 2008, Breast Cancer Research and Treatment.

Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease

A. Mes-Masson, D. Provencher, E. Carmona, 2020, Cancers.

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.

A. Mes-Masson, D. Provencher, P. Tonin, 2015, Oncology letters.

Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

A. Mes-Masson, D. Provencher, P. Tonin, 2012, Cancer Prevention Research.

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

D. Provencher, S. Memarzadeh, U. Matulonis, 2023, Gynecologic oncology.

Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.

A. Tinker, M. Köbel, D. Provencher, 2020, Gynecologic oncology.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

D. Provencher, M. Birrer, I. Vergote, 2019, Gynecologic oncology.

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

D. Matei, A. Oza, D. Provencher, 2019, Clinical Cancer Research.

Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p

A. Mes-Masson, D. Provencher, P. Tonin, 2007, Oncogene.

Selected class I and class II HLA alleles and haplotypes and risk of high‐grade cervical intraepithelial neoplasia

D. Provencher, E. Franco, A. Ferenczy, 2008, International journal of cancer.

Epidemiology and Natural History of HPV Infection

D. Provencher, D. Money, 2007 .

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2019, The Lancet. Oncology.

A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis

A. Mes-Masson, M. Köbel, D. Provencher, 2021, International journal of molecular sciences.

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer

A. Mes-Masson, D. Provencher, L. Buisseret, 2021, Journal for ImmunoTherapy of Cancer.

Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa

A. Mes-Masson, A. Oza, M. Köbel, 2020, Modern Pathology.

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.

C. Le Page, A. Mes-Masson, D. Provencher, 2019, Gynecologic oncology.

The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis

A. Mes-Masson, D. Provencher, V. Barrès, 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

T. Hudson, A. Mes-Masson, D. Provencher, 2002, Genome research.

Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.

A. Mes-Masson, D. Provencher, Diane Provencher, 2013, Journal of minimally invasive gynecology.

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

A. Mes-Masson, D. Provencher, P. Tonin, 2016, Oncotarget.

Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence.

D. Provencher, D. Donath, A. Alobaid, 2006, Gynecologic oncology.

Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion

A. Mes-Masson, D. Provencher, E. Carmona, 2019, Nature Communications.

Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

A. Talhouk, S. Leung, A. Tinker, 2022, Modern Pathology.

Morphologic three-dimensional scanning of fallopian tubes to assist ovarian cancer diagnosis

Nicolas Godbout, Fouzi Benboujja, Caroline Boudoux, 2017, Journal of biomedical optics.

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

B. Karlan, A. Oza, D. Provencher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2013, Molecular oncology.

Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer

C. Le Page, A. Mes-Masson, D. Provencher, 2006, International journal of cancer.

Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

A. Tinker, A. Oza, D. Provencher, 2020 .

The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent

A. Mes-Masson, W. Foulkes, D. Provencher, 2011, Breast Cancer Research and Treatment.

Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2010, Familial Cancer.

Vulvar Squamous Cell Carcinoma With Sarcomatoid Features are HPV-independent Lesions: A Subset are Also Associated With TP53-independent Lesions and Radiation Therapy

D. Provencher, K. Rahimi, S. Roy, 2022, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Predicting developmental relationships of tumor resident and circulating T cells in ovarian cancer

A. Mes-Masson, D. Provencher, S. Petropoulos, 2023, bioRxiv.

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer

A. Mes-Masson, A. Oza, D. Provencher, 2023, Scientific Reports.

Characterization of four novel epithelial ovarian cancer cell lines

A. Mes-Masson, D. Provencher, P. Tonin, 2000, In Vitro Cellular & Developmental Biology - Animal.

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors

A. Mes-Masson, D. Provencher, I. Laskov, 2015, BMC Medicine.

Molecular Genetic Analysis of a Cell Adhesion Molecule With Homology to L1CAM, Contactin 6, and Contactin 4 Candidate Chromosome 3p26pter Tumor Suppressor Genes in Ovarian Cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2009, International Journal of Gynecologic Cancer.

Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer.

D. Provencher, P. Saigo, S. Rubin, 1993 .

Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases

Trevor J Pugh, J. Ragoussis, C. Greenwood, 2023, Frontiers in Oncology.

Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.

D. Provencher, N. Letarte, J. Adam, 2017, Gynecologic oncology.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

D. Provencher, M. Gore, S. Chan, 2007, British Journal of Cancer.

Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women.

D. Provencher, S. Walmsley, F. Coutlée, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hormonal and reproductive factors and the risk of ovarian cancer

M. Abrahamowicz, A. Mes-Masson, D. Provencher, 2017, Cancer Causes & Control.

A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families

A. Mes-Masson, D. Provencher, P. Tonin, 2007, Familial Cancer.

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model

Anne-Marie Mes-Masson, Thomas J Hudson, T. Hudson, 2001, Oncogene.

3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Alcohol intake and the risk of epithelial ovarian cancer

M. Abrahamowicz, D. Provencher, W. Gotlieb, 2023, Cancer Causes & Control.

A novel method of cell embedding for tissue microarrays

J. Diallo, A. Mes-Masson, F. Saad, 2010, Histopathology.

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent

A. Mes-Masson, W. Foulkes, D. Provencher, 2006, Clinical genetics.

Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes

A. Mes-Masson, D. Provencher, P. Tonin, 2008, Molecular carcinogenesis.

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models

A. Mes-Masson, D. Provencher, E. Carmona, 2021, Scientific Reports.

DNA Damage Signaling and Apoptosis in Preinvasive Tubal Lesions of Ovarian Carcinoma

D. Provencher, V. Barrès, V. Ouellet, 2014, International Journal of Gynecologic Cancer.

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

H. Mackay, E. Eisenhauer, D. Provencher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.

C. Le Page, A. Mes-Masson, D. Provencher, 2010, Translational oncology.

Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.

D. Matei, A. Oza, D. Provencher, 2016 .

Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial

A. Tinker, A. Oza, D. Provencher, 2017 .

V. Gebski, D. Provencher, D. Eek, 2017 .

Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.

D. Provencher, J. Ledermann, T. Park-Simon, 2017 .

Directive clinique canadienne de consensus sur le virus du papillome humain

D. Provencher, A. Lalonde, J. Frappier, 2007 .

Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population

C. Greenwood, A. Mes-Masson, W. Foulkes, 2015, Clinical genetics.

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families

Anne-Marie Mes-Masson, A. Mes-Masson, W. Foulkes, 2006, BMC Medical Genetics.

The Meaning‐Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study

D. Provencher, N. Mayo, V. Lee, 2010, Psycho-oncology.

The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles

Anne-Marie Mes-Masson, A. Mes-Masson, D. Provencher, 2009, Journal of Translational Medicine.

Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer

A. Mes-Masson, D. Provencher, P. Tonin, 2009, Molecular carcinogenesis.

ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).

D. Provencher, R. Glasspool, B. Asselain, 2020 .

Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II

D. Provencher, D. Cruickshank, M. Widschwendter, 2019, International Journal of Gynecological Cancer.

NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer

A. Mes-Masson, D. Provencher, E. Carmona, 2021, Oncogene.

Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer

D. Provencher, S. Rubin, E. Stockert, 1994, Gynecologic oncology.

Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines

T. Hudson, A. Mes-Masson, D. Provencher, 2003, Oncogene.

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

A. Oberg, D. Provencher, I. Ray-Coquard, 2023, Gynecologic oncology.

Mapping of chromosome 3p deletions in human epithelial ovarian tumors

A. Mes-Masson, D. Provencher, P. Tonin, 1998, Oncogene.

Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221

A. Tinker, D. Provencher, L. Seymour, 2016 .

Laparoscopic staging of early ovarian cancer.

D. Provencher, C. Pomel, P. Gauthier, 1996, Gynecologic oncology.

Laparoscopic staging of early ovarian cancer.

D. Provencher, C. Pomel, P. Gauthier, 1995, Gynecologic oncology.

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines

A. Mes-Masson, D. Provencher, P. Tonin, 2008, BMC Medical Genomics.

Biomarkers in Epithelial Ovarian Cancer—or Should We Go with the Flow?

O. Guenat, A. Mes-Masson, D. Provencher, 2012 .

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.

Cesar M. Castro, A. Tinker, A. Oza, 2021, Gynecologic oncology.

Detection of human papillomavirus DNA in cervical lavage specimens by a nonisotopic consensus PCR assay

D. Provencher, F. Coutlée, H. Voyer, 1995, Journal of clinical microbiology.

Combination of serum biomarkers to differentiate malignant from benign ovarian tumours.

A. Mes-Masson, D. Provencher, A. Ferenczy, 2012, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps

A. Mes-Masson, D. Provencher, F. Gougeon, 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Authors' Reply

A. Mes-Masson, D. Huntsman, M. Köbel, 2010 .

Genetic and molecular analyses of candidate germline BRIP1/FANCJ variants implicated in breast and ovarian cancer

J. Ragoussis, A. Mes-Masson, D. Provencher, 2023, medRxiv.

Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia

D. Provencher, H. Trottier, A. Ferenczy, 2007, Cancer Epidemiology Biomarkers & Prevention.

From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer

T. Hudson, C. Le Page, A. Mes-Masson, 2006, International journal of cancer.

537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer

A. Oza, D. Provencher, A. Shields, 2022, Annals of Oncology.

ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).

D. Provencher, R. Glasspool, B. Asselain, 2019, Journal of Clinical Oncology.

Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary safety results from the phase II LIGHT study

D. Provencher, C. Aghajanian, K. Cadoo, 2021, Gynecologic Oncology.

Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.

D. Provencher, C. Aghajanian, K. Cadoo, 2021 .

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

A. Oza, R. Wenham, D. Provencher, 2015 .

Chylous ascites after pelvic lymph node dissection for gynecologic cancer.

D. Provencher, A. Alobaid, P. Gauthier, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

A. Tinker, A. Oza, D. Provencher, 2018, The Lancet. Oncology.

BTF4/BTNA3.2 and GCS as Candidate mRNA Prognostic Markers in Epithelial Ovarian Cancer

C. Le Page, A. Mes-Masson, D. Provencher, 2008, Cancer Epidemiology Biomarkers & Prevention.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.

D. Provencher, B. Rosen, T. Oliver, 2007, Gynecologic oncology.

833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer

Cesar M. Castro, D. Provencher, I. Vergote, 2020 .

A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)

A. Oza, D. Provencher, P. Ghatage, 2015 .